Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Rutgeerts

Showing results (1-10 of 315) with videos related to

Pageof 32
Sort By:
Gut|September 25, 1999
Budesonide led to a greater remission rate and fewer severe adverse events than did mesalamine in Crohn's diseaseP Rutgeerts
The American Journal of Gastroenterology|October 19, 2002
Infliximab for ulcerative colitis: the need for adequately powered placebo-controlled trialsP Rutgeerts
Gut|July 16, 2002
Protagonist: Crohn's disease recurrence can be prevented after ileal resectionP Rutgeerts
Scandinavian Journal of Gastroenterology. Supplement|June 12, 2003
Modern therapy for inflammatory bowel diseaseP Rutgeerts
Inflammatory Bowel Diseases|March 10, 2001
The use of budesonide in the treatment of active Crohn's disease is good clinical practiceP Rutgeerts
Inflammatory Bowel Diseases|June 1, 2000
Infliximab is the drug we have been waiting for in Crohn's diseaseP Rutgeerts
Alimentary Pharmacology & Therapeutics|September 9, 2004
Review article: treatment of perianal fistulizing Crohn's diseaseP Rutgeerts
The Netherlands Journal of Medicine|August 1, 1994
Recurrence of Crohn's disease in the neoterminal ileum after ileal resection: is prevention therapy possible?P Rutgeerts
Gastroenterologia Y Hepatologia|January 1, 1996
Clinical risk factors determining recurrence in Crohn's diseaseP Rutgeerts
Alimentary Pharmacology & Therapeutics|April 1, 1989
Comparative efficacy of coated, oral 5-aminosalicylic acid (Claversal) and sulphasalazine for maintaining remission of ulcerative colitis. International Study GroupP Rutgeerts
Pageof 32

Showing results (1-10 of 315) with videos related to

Sort By:
Pageof 32
Gut|September 25, 1999
Budesonide led to a greater remission rate and fewer severe adverse events than did mesalamine in Crohn's diseaseP Rutgeerts
The American Journal of Gastroenterology|October 19, 2002
Infliximab for ulcerative colitis: the need for adequately powered placebo-controlled trialsP Rutgeerts
Gut|July 16, 2002
Protagonist: Crohn's disease recurrence can be prevented after ileal resectionP Rutgeerts
Scandinavian Journal of Gastroenterology. Supplement|June 12, 2003
Modern therapy for inflammatory bowel diseaseP Rutgeerts
Inflammatory Bowel Diseases|March 10, 2001
The use of budesonide in the treatment of active Crohn's disease is good clinical practiceP Rutgeerts
Inflammatory Bowel Diseases|June 1, 2000
Infliximab is the drug we have been waiting for in Crohn's diseaseP Rutgeerts
Alimentary Pharmacology & Therapeutics|September 9, 2004
Review article: treatment of perianal fistulizing Crohn's diseaseP Rutgeerts
The Netherlands Journal of Medicine|August 1, 1994
Recurrence of Crohn's disease in the neoterminal ileum after ileal resection: is prevention therapy possible?P Rutgeerts
Gastroenterologia Y Hepatologia|January 1, 1996
Clinical risk factors determining recurrence in Crohn's diseaseP Rutgeerts
Alimentary Pharmacology & Therapeutics|April 1, 1989
Comparative efficacy of coated, oral 5-aminosalicylic acid (Claversal) and sulphasalazine for maintaining remission of ulcerative colitis. International Study GroupP Rutgeerts
Pageof 32